ImmunityBio (IBRX) is preparing to share new data at the Thoracic Rare Cancer Symposium in Ottawa on October 2, 2026. This is drawing fresh attention to how its immunotherapy pipeline is being valued.
Over the past year ImmunityBio has shifted from a niche biotech story to one that traders watch closely, with the latest symposium appearance adding to a series of catalysts that have coincided with very strong momentum. The share price has a 30 day return of 20.67% and a year to date share price return of 382.67%. The 1 year total shareholder return of 285.38% and 3 year total shareholder return of about 7x indicate that investors have already priced in a lot of optimism around the pipeline and future trial updates.
Spot fast-moving peers to ImmunityBio by scanning the hand-picked 35 healthcare AI stocks that are riding similar momentum around breakthrough treatments and trial headlines.
After a move this sharp in ImmunityBio, the real tension is simple: Do you lean into the momentum now or wait for the valuation math to offer a cleaner entry?
Most Popular Narrative: 25% Undervalued
On the Simply Wall St narrative, ImmunityBio screens as undervalued, with a fair value of $13 against a last close of $9.75. This raises the question of whether the recent price surge has fully caught up with the growth story that analysts have mapped out using a 7.4% discount rate.
The integration of AI driven tools like askIB into R&D, manufacturing and commercial operations, along with the NANT Leonardo robotic cell manufacturing platform, is aimed at higher throughput and lower unit costs. This can support margin improvement as volumes scale and help narrow losses over time.
See why 15 investors see ImmunityBio as 25% undervalued .
Result: Fair Value of $13 (UNDERVALUED)
Still, the ImmunityBio story can change quickly if regulators push back on new ANKTIVA indications or if competitors capture key bladder and lung cancer patients.
Find out about the key risks to this ImmunityBio narrative .
Next Steps
Mixed signals on ImmunityBio so far. If the mix of excitement and risk feels familiar, move quickly to weigh both sides through the 3 key rewards and 1 important warning sign
Looking for more ImmunityBio-sized ideas?
If ImmunityBio has your attention, do not stop here. Use the wider screener set to spot fresh opportunities before other investors even look up.
-
Target potential bargains across quality businesses by running through the 29 high quality undervalued stocks that still trade below their assessed worth.
-
Prioritise resilience and sleep-better-at-night holdings by checking the 31 resilient stocks with low risk scores that screen well on financial strength and risk metrics.
-
Hunt for future standouts by scanning the 20 high quality undiscovered gems that combine solid fundamentals with relatively low market attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include IBRX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
